Myomo, Inc. Logo

Myomo, Inc.

MYO

(1.0)
Stock Price

4,66 USD

-58.35% ROA

-93.09% ROE

-15.55x PER

Market Cap.

118.787.394,00 USD

3.76% DER

0% Yield

-44.75% NPM

Myomo, Inc. Stock Analysis

Myomo, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Myomo, Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (4%), which means it has a small amount of debt compared to the ownership it holds

2 Revenue Growth

This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.

3 ROE

The stock's ROE indicates a negative return (-106.1%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-65.09%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

5 PBV

The stock's high Price-to-Book Value (P/BV) ratio (9.17x) suggests it's overvalued, potentially making it an expensive investment.

6 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

7 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Graham Number

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (-2) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Myomo, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Myomo, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Myomo, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Myomo, Inc. Revenue
Year Revenue Growth
2014 913.254
2015 689.671 -32.42%
2016 1.103.277 37.49%
2017 1.558.866 29.23%
2018 2.444.104 36.22%
2019 3.837.730 36.31%
2020 7.583.371 49.39%
2021 13.856.374 45.27%
2022 15.555.229 10.92%
2023 20.318.092 23.44%
2023 19.241.158 -5.6%
2024 30.083.068 36.04%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Myomo, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2014 675.211
2015 869.130 22.31%
2016 1.120.951 22.46%
2017 1.751.731 36.01%
2018 1.838.633 4.73%
2019 2.160.588 14.9%
2020 1.669.188 -29.44%
2021 2.557.367 34.73%
2022 2.482.489 -3.02%
2023 2.869.024 13.47%
2023 2.636.487 -8.82%
2024 4.028.892 34.56%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Myomo, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2014 2.848.283
2015 3.102.237 8.19%
2016 2.933.564 -5.75%
2017 5.849.969 49.85%
2018 10.405.609 43.78%
2019 11.252.822 7.53%
2020 12.975.194 13.27%
2021 14.435.675 10.12%
2022 14.373.511 -0.43%
2023 0 0%
2023 15.561.345 100%
2024 10.624.868 -46.46%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Myomo, Inc. EBITDA
Year EBITDA Growth
2014 -2.735.158
2015 -3.528.196 22.48%
2016 -3.267.271 -7.99%
2017 -1.346.250 -142.69%
2018 -10.495.004 87.17%
2019 -10.894.364 3.67%
2020 -10.394.016 -4.81%
2021 -9.932.102 -4.65%
2022 -10.129.577 1.95%
2023 -8.097.476 -25.1%
2023 -7.713.870 -4.97%
2024 -4.054.716 -90.24%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Myomo, Inc. Gross Profit
Year Gross Profit Growth
2014 701.674
2015 445.264 -57.59%
2016 821.113 45.77%
2017 1.053.586 22.06%
2018 1.715.825 38.6%
2019 2.920.107 41.24%
2020 4.982.996 41.4%
2021 10.312.277 51.68%
2022 10.253.096 -0.58%
2023 13.955.392 26.53%
2023 13.182.383 -5.86%
2024 21.302.048 38.12%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Myomo, Inc. Net Profit
Year Net Profit Growth
2014 -3.527.796
2015 -4.482.167 21.29%
2016 -3.617.022 -23.92%
2017 -12.097.479 70.1%
2018 -10.316.739 -17.26%
2019 -10.631.015 2.96%
2020 -12.038.620 11.69%
2021 -10.372.329 -16.06%
2022 -10.721.022 3.25%
2023 -8.116.064 -32.1%
2023 -8.147.565 0.39%
2024 -4.486.428 -81.6%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Myomo, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2014 -106
2015 -135 20.9%
2016 -1 0%
2017 -84 100%
2018 -25 -236%
2019 -19 -31.58%
2020 -4 -533.33%
2021 -2 -200%
2022 -2 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Myomo, Inc. Free Cashflow
Year Free Cashflow Growth
2014 -2.550.571
2015 -3.362.450 24.15%
2016 -3.204.535 -4.93%
2017 -6.220.421 48.48%
2018 -9.733.177 36.09%
2019 -10.393.808 6.36%
2020 -9.078.648 -14.49%
2021 -9.874.157 8.06%
2022 -10.345.335 4.55%
2023 -6.318.580 -63.73%
2023 -1.768.899 -257.2%
2024 -2.035.289 13.09%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Myomo, Inc. Operating Cashflow
Year Operating Cashflow Growth
2014 -2.547.045
2015 -3.334.506 23.62%
2016 -3.202.670 -4.12%
2017 -6.153.419 47.95%
2018 -9.606.310 35.94%
2019 -10.341.817 7.11%
2020 -9.032.896 -14.49%
2021 -9.547.695 5.39%
2022 -10.233.542 6.7%
2023 -6.172.764 -65.79%
2023 -1.714.806 -259.97%
2024 -1.915.924 10.5%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Myomo, Inc. Capital Expenditure
Year Capital Expenditure Growth
2014 3.526
2015 27.944 87.38%
2016 1.865 -1398.34%
2017 67.002 97.22%
2018 126.867 47.19%
2019 51.991 -144.02%
2020 45.752 -13.64%
2021 326.462 85.99%
2022 111.793 -192.02%
2023 145.816 23.33%
2023 54.093 -169.57%
2024 119.365 54.68%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Myomo, Inc. Equity
Year Equity Growth
2014 712.110
2015 -1.338.161 153.22%
2016 -17.530.456 92.37%
2017 12.445.778 240.85%
2018 6.425.885 -93.68%
2019 1.824.708 -252.16%
2020 11.565.374 84.22%
2021 15.409.131 24.94%
2022 6.359.365 -142.31%
2023 8.989.350 29.26%
2023 11.023.111 18.45%
2024 9.677.711 -13.9%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Myomo, Inc. Assets
Year Assets Growth
2014 3.045.070
2015 1.508.864 -101.81%
2016 1.658.252 9.01%
2017 13.974.992 88.13%
2018 8.281.572 -68.75%
2019 6.598.693 -25.5%
2020 14.709.782 55.14%
2021 20.095.412 26.8%
2022 10.162.006 -97.75%
2023 14.581.568 30.31%
2023 17.053.965 14.5%
2024 16.190.380 -5.33%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Myomo, Inc. Liabilities
Year Liabilities Growth
2014 2.332.960
2015 2.847.025 18.06%
2016 19.188.708 85.16%
2017 1.529.214 -1154.81%
2018 1.855.687 17.59%
2019 4.773.985 61.13%
2020 3.144.408 -51.82%
2021 4.686.281 32.9%
2022 3.802.641 -23.24%
2023 5.592.218 32%
2023 6.030.854 7.27%
2024 6.512.670 7.4%

Myomo, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.56
Net Income per Share
-0.25
Price to Earning Ratio
-15.55x
Price To Sales Ratio
5.63x
POCF Ratio
-15.91
PFCF Ratio
-12.51
Price to Book Ratio
15.17
EV to Sales
5.37
EV Over EBITDA
-12.33
EV to Operating CashFlow
-12.27
EV to FreeCashFlow
-11.93
Earnings Yield
-0.06
FreeCashFlow Yield
-0.08
Market Cap
0,12 Bil.
Enterprise Value
0,11 Bil.
Graham Number
1.21
Graham NetNet
0.15

Income Statement Metrics

Net Income per Share
-0.25
Income Quality
0.98
ROE
-0.93
Return On Assets
-0.58
Return On Capital Employed
-0.97
Net Income per EBT
1.03
EBT Per Ebit
0.97
Ebit per Revenue
-0.45
Effective Tax Rate
-0.03

Margins

Sales, General, & Administrative to Revenue
0.63
Research & Developement to Revenue
0.17
Stock Based Compensation to Revenue
0.04
Gross Profit Margin
0.67
Operating Profit Margin
-0.45
Pretax Profit Margin
-0.43
Net Profit Margin
-0.45

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.25
Free CashFlow per Share
-0.25
Capex to Operating CashFlow
-0.03
Capex to Revenue
0.01
Capex to Depreciation
0.67
Return on Invested Capital
-0.97
Return on Tangible Assets
-0.58
Days Sales Outstanding
43.68
Days Payables Outstanding
72.55
Days of Inventory on Hand
137.74
Receivables Turnover
8.36
Payables Turnover
5.03
Inventory Turnover
2.65
Capex per Share
0.01

Balance Sheet

Cash per Share
0,24
Book Value per Share
0,26
Tangible Book Value per Share
0.26
Shareholders Equity per Share
0.26
Interest Debt per Share
0.01
Debt to Equity
0.04
Debt to Assets
0.02
Net Debt to EBITDA
0.6
Current Ratio
2.34
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
0,01 Bil.
Invested Capital
9505158
Working Capital
0,01 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
2493800.5
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Myomo, Inc. Dividends
Year Dividends Growth

Myomo, Inc. Profile

About Myomo, Inc.

Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.

CEO
Mr. Paul R. Gudonis
Employee
101
Address
137 Portland Street
Boston, 02114

Myomo, Inc. Executives & BODs

Myomo, Inc. Executives & BODs
# Name Age
1 Ms. Galina Shtivelman
Senior Director of Human Resources
70
2 Colin Anderson
Global Director of Operations
70
3 Dr. Harry Kovelman M.D.
Chief Medical Officer
70
4 Mr. Joseph Chicoskie
Director of Marketing
70
5 Mr. Micah J. Mitchell
Chief Commercial Officer
70
6 Mr. Paul R. Gudonis
Chairman, President & Chief Executive Officer
70
7 Mr. David A. Henry
Chief Financial Officer
70

Myomo, Inc. Competitors